Tumor Biology

, Volume 37, Issue 2, pp 2547–2553 | Cite as

Autoantibody response to Sui1 and its tissue-specific expression in hepatocellular carcinoma

  • Jian-Wei Zhou
  • Yuan Li
  • Li-Xia Yue
  • Cheng-Lin Luo
  • Yao Chen
  • Jian-Ying Zhang
Original Article


To investigate the immunogenicity of Homo sapiens putative translation initiation factor (Sui1) in hepatocellular carcinoma (HCC), enzyme-linked immunosorbent assay (ELISA) and Western blot were utilized to assess autoantibody responses to Sui1 in sera from HCC patients and healthy individuals. Indirect immunofluorescence (IIF) assay with cancer cells and immunohistochemistry (IHC) study with tissue array slides were performed to examine Sui1 expression profile in cancer cells and tissues. The data confirmed that the frequency of autoantibody to Sui1 in sera of HCC patients was 15.5 % (16/103), which was remarkably higher than that in sera of liver cirrhosis (LC) patients (3.3 %, 1/30), chronic hepatitis (CH) patients (0 %, 0/29), and normal human serum (NHS) (0 %, 0/82) (p < 0.01). IHC study showed that the Sui1 expression in HCC tissues was 26.7 % (16/60). The expression of Sui1 had the trend of increasing along with the cancer grades but no statistical significance (p > 0.05). In immunodiagnosis of HCC, the sensitivity and specificity of the anti-Sui1 antibody were 15.5 and 99.3 %, respectively. If both anti-Sui1 and alpha fetal protein (AFP) were simultaneously utilized as detective markers, 66.7 % (30/45) of HCC patients could be correctly distinguished. The results suggested that anti-Sui1 could be utilized as a supplementary serological marker for the detection of HCC and Sui1 might be associated to HCC carcinogenesis.


Sui1 Tumor-associated antigen Hepatocellular carcinoma Immunoreactivity Autoantibody 



This work was supported by a grant (SC1CA166016) from the National Institutes of Health (NIH). We also thank the Border Biological Research Center (BBRC) Core Facilities at The University of Texas at El Paso (UTEP) for their support, which were funded by a NIH grant (5G12MD007592).

Conflicts of interest



  1. 1.
    Zhang JY, Tan EM. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn. 2010;10(3):321–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y, Chan EK. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol. 2007;46(1):107–14.CrossRefPubMedGoogle Scholar
  3. 3.
    Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21(32):5006–15.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang K, Chen Y, Liu S, Qiu S, Gao S, Huang X, et al. Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma. Int J Immunopathol Pharmacol. 2009;22(3):459–67.CrossRefGoogle Scholar
  5. 5.
    Fernandez Madrid F, Tang N, Alansari H, Karvonen RL, Tomkiel JE. Improved approach to identify cancer-associated autoantigens. Autoimmun Rev. 2005;4(4):230–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Hinnebusch AG. The scanning mechanism of eukaryotic translation initiation. Annu Rev Biochem. 2014;83:779–812.CrossRefPubMedGoogle Scholar
  7. 7.
    Martin-Marcos P, Cheung YN, Hinnebusch AG. Functional elements in initiation factors 1, 1A, and 2beta discriminate against poor AUG context and non-AUG start codons. Mol Cell Biol. 2011;31(23):4814–31.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chen Y, Zhou Y, Qiu S, Wang K, Liu S, Peng XX, et al. Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett. 2010;289(1):32–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhang JY, Chan EK, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med. 1999;189(7):1101–10.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S108–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMedGoogle Scholar
  12. 12.
    Tang ZY. Hepatocellular carcinoma surgery—review of the past and prospects for the 21st century. J Surg Oncol. 2005;91(2):95–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC, Zhang JY. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res. 2008;7(9):4004–12.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang J, Wang K, Zhang J, Liu SS, Dai L, Zhang JY. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res. 2011;10(6):2863–72.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dai L, Ren P, Liu M, Imai H, Tan EM, Zhang JY. Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma. Clin Immunol. 2014;152(1–2):127–39.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Herrmannova A, Daujotyte D, Yang J-C, Cuchalova L, Gorrec F, Wagner S, et al. Structural analysis of an eIF3 subcomplex reveals conserved interactions required for a stable and proper translation pre-initiation complex assembly. Nucleic Acids Res. 2012;40(5):2294–311.CrossRefPubMedGoogle Scholar
  17. 17.
    Hussain T, Llacer JL, Fernandez IS, Munoz A, Martin-Marcos P, Savva CG, et al. Structural changes enable start codon recognition by the eukaryotic translation initiation complex. Cell. 2014;159(3):597–607.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Chin LS, Singh SK, Wang Q, Murray SF. Identification of okadaic-acid-induced genes by mRNA differential display in glioma cells. J Biomed Sci. 2000;7(2):152–9.CrossRefPubMedGoogle Scholar
  19. 19.
    van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol. 2009;27(4):542–9.CrossRefPubMedGoogle Scholar
  20. 20.
    van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, van Agthoven TL, Sarwari R, et al. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer. 2010;17(1):215–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Lian Z, Pan J, Liu J, Zhang S, Zhu M, Arbuthnot P, et al. The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene. 1999;18(9):1677–87.CrossRefPubMedGoogle Scholar
  22. 22.
    Bilanges B, Stokoe D. Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene. 2007;26(41):5973–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med. 2004;10(5):484–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003;3(3):179–92.CrossRefPubMedGoogle Scholar
  25. 25.
    Mazan-Mamczarz K, Hagner P, Dai B, Corl S, Liu Z, Gartenhaus RB. Targeted suppression of MCT-1 attenuates the malignant phenotype through a translational mechanism. Leuk Res. 2009;33(3):474–82.CrossRefPubMedGoogle Scholar
  26. 26.
    Sullivan CAW, Chung GG. Biomarker validation: in situ analysis of protein expression using semiquantitative immunohistochemistry-based techniques. Clin Colorectal Cancer. 2008;7(3):172–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Jian-Wei Zhou
    • 1
    • 2
  • Yuan Li
    • 2
    • 3
  • Li-Xia Yue
    • 2
    • 4
  • Cheng-Lin Luo
    • 2
  • Yao Chen
    • 2
  • Jian-Ying Zhang
    • 2
  1. 1.Department of OncologyPeople’s Hospital of Zhengzhou University (Henan Provincial People’s Hospital)ZhengzhouChina
  2. 2.Department of Biological SciencesThe University of Texas at El PasoEl PasoUSA
  3. 3.Department of StomatologyZhengzhou First People’s HospitalZhengzhouChina
  4. 4.Surgical DepartmentPeople’s Hospital of Zhengzhou University (Henan Provincial People’s Hospital)ZhengzhouChina

Personalised recommendations